Document Detail

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
MedLine Citation:
PMID:  20593977     Owner:  NLM     Status:  MEDLINE    
We have previously shown that expression of CD40 has a favorable prognostic impact in diffuse large B-cell lymphoma (DLBCL) after anthracycline-based chemotherapy. Here we examined the prognostic value of immunohistochemically defined CD40 expression in 95 patients with DLBCL treated with both anthracycline-based chemotherapy and rituximab. Using a 10% cut-off level, 77% of the patients had CD40-positive tumors and showed a superior overall survival (p = 0.02 log-rank, hazard ratio 0.35, 95% CI 0.14-0.88, p = 0.03 Cox regression). When adjusted for International Prognostic Index in multivariate analysis, CD40 was not an independent prognostic factor (hazard ratio 0.39, 95% CI 0.15-1.04, p = 0.06 Cox regression). However, even after the introduction of immunochemotherapy, CD40 has a potential prognostic impact in DLBCL. Additional and larger studies are necessary, regarding the immunohistochemical robustness of CD40 and the biological mechanisms that contribute to the superior prognosis in CD40-expressing DLBCL.
Karin Rydström; Johan Linderoth; Heidi Nyman; Mats Ehinger; Patrick Joost; Pär-Ola Bendahl; Sirpa Leppä; Mats Jerkeman
Related Documents :
20576437 - Incidence and management of high grade glioma in māori and non-māori patients.
18953067 - Initial experience with conservative treatment in cancer patients with osteonecrosis of...
6891627 - Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy.
15345027 - Survival of patients with metastatic breast cancer: twenty-year data from two seer regi...
22027547 - 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than ...
2437347 - Mesangial proliferative glomerulonephritis. natural history and effects of dextran sulf...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  51     ISSN:  1029-2403     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-02     Completed Date:  2010-12-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  England    
Other Details:
Languages:  eng     Pagination:  1643-8     Citation Subset:  IM    
Department of Oncology, Institution of Clinical Sciences, Lund University and Lund University Hospital, Lund, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antigens, CD40 / metabolism*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / administration & dosage
DNA-Binding Proteins / metabolism
Doxorubicin / administration & dosage
Immunoenzyme Techniques
Interferon Regulatory Factors / metabolism
Lymphoma, Large B-Cell, Diffuse / drug therapy*,  immunology,  metabolism*
Middle Aged
Prednisone / administration & dosage
Proto-Oncogene Proteins c-bcl-2 / metabolism
Survival Rate
Tumor Markers, Biological / metabolism*
Vincristine / administration & dosage
Young Adult
Reg. No./Substance:
0/Antibodies, Monoclonal, Murine-Derived; 0/Antigens, CD40; 0/BCL6 protein, human; 0/DNA-Binding Proteins; 0/Interferon Regulatory Factors; 0/Proto-Oncogene Proteins c-bcl-2; 0/Tumor Markers, Biological; 0/interferon regulatory factor-4; 0/rituximab; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine
Comment In:
Leuk Lymphoma. 2010 Sep;51(9):1588-9   [PMID:  20807090 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Spontaneous twin anemia?polycythemia sequence complicated by recipient placental vascular thrombosis...
Next Document:  Extramedullary relapse of acute myeloid leukemia in a surgical wound.